HR 3873 Re-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click.
To increase funding for cancer research by the National Cancer Institute to be more in proportion to the mortality rates of cancer.
Summary
This bill increases federal funding for cancer research and requires a study of cancer drug shortages. The bill appropriates additional funding to the National Cancer Institute for each fiscal year from 2026 through 2030, equal to 25 percent of the total amount appropriated to the Institute in fiscal year 2022, on top of regular appropriations. The bill also directs the Secretary of Health and Human Services and the Food and Drug Administration to study the reasons for cancer drug shortages, including economic factors, supply chain failures, drug development and approval delays, and insufficient availability of generic and biosimilar drugs. The FDA must submit a report to Congress within one year with findings and recommendations for addressing cancer drug shortages.
AI-generated plain-language summary of the bill text — neutral, and may be imperfect. See the full text below for the exact wording.
Sponsor (1)
6 cosponsors
Money behind the sponsor
Top reported contributors to Brian K. Fitzpatrick’s campaign committee (2024 cycle) — who funds the bill’s sponsor, not a claim about this bill. Data from FEC.
Organizations whose employees gave the most — itemized individual contributions grouped by the donor’s reported employer (FEC Schedule A). Full finance for Brian K. Fitzpatrick → · Outside spending →
Actions (2)
- Jun 10, 2025 Referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. · house
- Jun 10, 2025 Introduced in House
Similar bills (6)
Bills with similar text or summary — includes reintroductions across Congresses. Ranked by semantic similarity of the bill text (computed locally); a neutral discovery aid, not a claim the bills are duplicates.
Text versions (1)
Bills are re-published as they move (Introduced → Reported → Engrossed → Enrolled …). Each stage below is a separate text; pick two to see what changed. Data from Congress.gov.
Full text
IN THE HOUSE OF REPRESENTATIVES
June 10, 2025
Mr. Fitzpatrick (for himself and Mrs. Dingell) introduced the following bill; which was referred to the Committee on Appropriations, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned
A BILL
To increase funding for cancer research by the National Cancer Institute to be more in proportion to the mortality rates of cancer.
Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the “Knock Out Cancer Act” or the “KO Cancer Act”.
SEC. 2. FINDINGS.
Congress finds the following:
(1) Cancer is one of the leading causes of death in the world and has touched nearly every life, either directly or indirectly.
(2) Cancer is the cause of nearly 1 out of every 4 deaths in the United States, since 2000 totaling over 15 million American lives.
(3) Efforts to increase awareness of cancer symptoms among patients and clinicians would lead to earlier detection and improvements in survival rates.
(4) Scientific understanding and research lead to innovations in effective treatments, controls, and cures for cancer.
(5) The National Cancer Institute has been a leader in finding medical breakthroughs for treatment and therapies for cancer patients.
(6) Through substantial investment in cancer research, potentially even the tripling of necessary funding, the United States will be best able to address the mortality rates of cancer and the impacts on the patient population.
SEC. 3. INCREASING NCI BUDGET FOR CANCER RESEARCH.
To conduct or support cancer research, there is hereby appropriated, for each of fiscal years 2026 through 2030, to the National Cancer Institute, out of amounts in the Treasury not otherwise appropriated, an amount that is equal to 25 percent of the total amount appropriated to the National Cancer Institute for fiscal year 2022, to remain available until expended. Amounts appropriated pursuant to the preceding sentence shall be in addition to amounts otherwise made available to the National Cancer Institute.
SEC. 4. REPORT TO CONGRESS ON CANCER DRUG SHORTAGES.
(a) Study.—The Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, in collaboration with such other agencies as the Secretary deems necessary, shall study the reasons for cancer drug shortages, including—
(1) economic reasons;
(2) supply chain failures;
(3) delays and other complications relating to—
(A) the development of cancer drugs; and
(B) the approval of such drugs by the Food and Drug Administration; and
(4) insufficient generic drugs and biosimilar biological products.
(b) Report.—
(1) In general.—Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall complete the study under subsection (a) and submit a report to the appropriate committees of the Congress on the results of such study.
(2) Recommendations.—The report under paragraph (1) shall include recommendations for addressing the reasons for cancer drug shortages. <all>
Comments